Regen BioPharma, Inc. Stock Other OTC
Equities
RGBP
US75886M1027
Biotechnology & Medical Research
Sales 2022 | 236K 323K | Sales 2023 | 237K 325K | Capitalization | 6.33M 8.68M |
---|---|---|---|---|---|
Net income 2022 | 2M 2.74M | Net income 2023 | 1M 1.37M | EV / Sales 2022 | 144 x |
Net Debt 2022 | 1.22M 1.68M | Net Debt 2023 | 635K 871K | EV / Sales 2023 | 29.4 x |
P/E ratio 2022 |
13.7
x | P/E ratio 2023 |
6.24
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.99% |
Managers | Title | Age | Since |
---|---|---|---|
David Koos
CEO | Chief Executive Officer | 64 | 12-04-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Koos
CEO | Chief Executive Officer | 64 | 12-04-23 |
1st Jan change | Capi. | |
---|---|---|
+2.93% | 106B | |
+7.02% | 23.47B | |
-14.60% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-8.83% | 16.78B | |
+5.51% | 14.41B | |
+37.49% | 12.86B | |
+329.39% | 8.78B |